Enteric Disease Testing Market by Product, Disease Type, Diagnostic Techniques, Testing Site

List of Tables

[198 Pages Report] The Enteric Disease Testing Market size was estimated at USD 4.31 billion in 2023 and expected to reach USD 4.54 billion in 2024, at a CAGR 5.47% to reach USD 6.26 billion by 2030.

Enteric disease testing encompasses a variety of diagnostic procedures aimed at identifying pathogens that cause infectious diseases affecting the gastrointestinal tract. Given the critical role of early and accurate diagnosis in managing and preventing the spread of these diseases, the need for enteric disease testing is driven by factors such as the growing global prevalence of enteric diseases, advancements in diagnostic technologies, and increased awareness and healthcare spending. However, the practice faces challenges such as the high costs associated with advanced testing technologies, limited accessibility in low-resource settings, and the need for skilled personnel to conduct and interpret tests. To address these issues, there is an ongoing focus on developing cost-effective and user-friendly diagnostic solutions that can be deployed widely, including in resource-constrained environments. The integration of molecular diagnostics, point-of-care testing, and the application of artificial intelligence and machine learning to improve test accuracy and speed is expected to diversify the testing procedures.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.31 billion
Estimated Year [2024]	USD 4.54 billion
Forecast Year [2030]	USD 6.26 billion
CAGR (%)	5.47%

Regional Insights

In the Americas, especially the United States and Canada, there is a high adoption rate of advanced diagnostic solutions, including molecular diagnostics and point-of-care testing, driven by robust healthcare systems and high healthcare expenditure. Companies in this region benefit from a conducive regulatory environment and significant investment in R&D, leading to rapid innovation and production of enteric disease testing solutions. The APAC region has a growing demand for enteric disease diagnostics due to increasing awareness of diseases such as cholera and typhoid coupled with rising healthcare spending. However, the market is characterized by a mix of advanced and traditional diagnostic practices, with significant variations in healthcare infrastructure across countries. Production in APAC is growing, with local companies emerging alongside established global players. EMEA presents a diverse picture, with highly developed markets in Western Europe employing cutting-edge diagnostic technologies while countries in Africa and parts of the Middle East grapple with challenges related to access and affordability of enteric disease testing. Regulatory environments across EMEA vary widely, affecting the pace of adoption of new technologies. Companies operating in EMEA are balancing innovation with cost-effective production to meet the needs of a diverse patient population.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Enteric Disease Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of enteric diseases due to poor sanitation and contaminated water supplies
- Technological innovations in diagnostic tests offer greater sensitivity, specificity, and faster results
- Governmental and non-governmental organizations' initiatives to control infectious diseases

Market Restraints
- High cost of advanced tests and the lack of infrastructure in emerging countries

Market Opportunities
- Increasing investment in healthcare infrastructure and the focus on preventive diagnostics
- Strategic partnerships and collaborations for R&D activities and market expansion

Market Challenges
- Regulations concerning the approval and commercialization of product

Market Segmentation Analysis
- Disease Type: Increasing preference for multiplex and molecular diagnostic methods for bacterial testing
- Testing Site: Need for rapid diagnostics crucial for immediate patient care in hospitals

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Enteric Disease Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Enteric Disease Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Clears MeMed BV Direct from Whole Blood

MeMed announced that its innovative MeMed BV test, designed for rapid differentiation between bacterial and viral infections, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for whole blood samples. This significant milestone allows healthcare professionals to leverage the MeMed Key analyzer, a leading-edge point-of-care device, to diagnose infections accurately in as little as 15 minutes. This breakthrough underscores MeMed's commitment to advancing host response technology and improving patient care by enabling timely and precise treatment decisions. [Published On: 2023-07-19]

Avacta Acquires European Diagnostic Test Maker

Avacta Group, a notable entity in the biotechnology sector, strategically expanded its portfolio by acquiring Coris Bioconcept SRL, a distinguished European producer of rapid diagnostic test kits. Coris Bioconcept specializes in developing, manufacturing, and commercializing lateral flow tests primarily intended for use by healthcare professionals. The company boasts a robust global distribution network, reaching markets across Europe, Asia, South America, Africa, and Oceania, enhancing its presence and operational reach in diagnostic testing. [Published On: 2023-06-01]

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

Merck, internationally known as MSD, announced its strategic move to acquire Prometheus Biosciences, Inc., a company in the biotechnological realm focusing on precision medicine methodologies for immune-mediated diseases. This acquisition set the transaction at an impressive total equity value of around USD 10.8 billion. Prometheus, recognized for its innovative approach to developing therapeutic and companion diagnostic solutions, is currently in the clinical stage. This partnership underscores Merck's commitment to advancing healthcare solutions by integrating cutting-edge technology and scientific research into its comprehensive portfolio. [Published On: 2023-04-16]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Enteric Disease Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Enteric Disease Testing Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Als Limited, Asure Quality, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerica Inc., bioMerieux SA, Bureau Veritas Group, Cepheid Inc., Coris BioConcept SPRL, DiaSorin, Eurofins Scientific SE, Hardy Diagnostics, Intertek Group PLC, Merck & Co., Inc., Merck KGAA, Meridian Bioscience Inc., Merieux NutriSciences Corporation, Neogen Corporation, Nova Biologicals, Perkinelmer, Inc., Qiagen N.V., Quest Diagnostics, Romer Labs Division Holding GmbH, SGS SA, Symbio Laboratories, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and TUV SUD AG.

Market Segmentation & Coverage

This research report categorizes the Enteric Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Consumables
- Kits
- Reagents

Disease Type
- Bacterial
  - Cholera
  - Escherichia coli
  - Salmonellosis

Parasitic
Viral

Diagnostic Techniques
- Immunoassays
- Molecular Diagnostics
  - PCR
  - Real-time PCR

Rapid Diagnostics
- Dipsticks
- Lateral Flow Assays

Testing Site
- In-Hospital
- Point-of-Care
- Standalone Laboratories

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-732E7CFCB4A5

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of enteric diseases due to poor sanitation and contaminated water supplies
  - 5.1.1.2. Technological innovations in diagnostic tests offer greater sensitivity, specificity, and faster results
  - 5.1.1.3. Governmental and non-governmental organizations' initiatives to control infectious diseases
- 5.1.2. Restraints
  - 5.1.2.1. High cost of advanced tests and the lack of infrastructure in emerging countries
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing investment in healthcare infrastructure and the focus on preventive diagnostics
  - 5.1.3.2. Strategic partnerships and collaborations for R&D activities and market expansion
- 5.1.4. Challenges
  - 5.1.4.1. Regulations concerning the approval and commercialization of product
5.2. Market Segmentation Analysis
- 5.2.1. Disease Type: Increasing preference for multiplex and molecular diagnostic methods for bacterial testing
- 5.2.2. Testing Site: Need for rapid diagnostics crucial for immediate patient care in hospitals
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Enteric Disease Testing Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Kits
6.4. Reagents

7. Enteric Disease Testing Market, by Disease Type

7.1. Introduction
7.2. Bacterial
7.3. Parasitic
7.4. Viral

8. Enteric Disease Testing Market, by Diagnostic Techniques

8.1. Introduction
8.2. Immunoassays
8.3. Molecular Diagnostics
8.4. Rapid Diagnostics

9. Enteric Disease Testing Market, by Testing Site

9.1. Introduction
9.2. In-Hospital
9.3. Point-of-Care
9.4. Standalone Laboratories

10. Americas Enteric Disease Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Enteric Disease Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Enteric Disease Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. FDA Clears MeMed BV Direct from Whole Blood
- 13.3.2. Avacta Acquires European Diagnostic Test Maker
- 13.3.3. Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio